PDCD1 and neoplasm: It is possible that combination therapy of anti-CD47 antibody, which increases the tumor cell phagocytosis and priming of anti-tumor CD8+ T cell responses, and anti-CTLA4/PD1, which reinvigorates exhausted T cells, may give greater synergism by improving different steps to generating effective anti-tumor immunity.